An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

[1] Isaacs A(1957)Virus interference. I. the interferon Proc R Soc London Ser B, Biol Sci 147 258-267

[2] Lindenmann J(2011)The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis Eur J Neurol 18 69-77

[3] Devonshire V(2014)Interferon β-1a for multiple sclerosis: old drug, new clothes Lancet Neurol 13 638-639

[4] Lapierre Y(2010)PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis J Interf Cytokine Res 30 777-785

[5] Macdonell R(2003)Pharmacokinetics of peginterferons Semin Liver Dis 23 23-28

[6] Ramo-Tello C(2000)Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 1666-1672

[7] Patti F(2001)A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology. 34 395-403

[8] Fontoura P(2012)A novel PEGylated interferon Beta-1a for multiple sclerosis: safety, pharmacology, and biology J Clin Pharmacol 52 798-808

[9] Hartung H-P(2016)COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects Br J Clin Pharmacol 82 380-388

[10] Baker DP(2015)Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE Mult Scler 21 1025-1035

[1] Isaacs A(1957)Virus interference. I. the interferon Proc R Soc London Ser B, Biol Sci 147 258-267

[2] Lindenmann J(2011)The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis Eur J Neurol 18 69-77

[3] Devonshire V(2014)Interferon β-1a for multiple sclerosis: old drug, new clothes Lancet Neurol 13 638-639

[4] Lapierre Y(2010)PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis J Interf Cytokine Res 30 777-785

[5] Macdonell R(2003)Pharmacokinetics of peginterferons Semin Liver Dis 23 23-28

[6] Ramo-Tello C(2000)Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 1666-1672

[7] Patti F(2001)A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology. 34 395-403

[8] Fontoura P(2012)A novel PEGylated interferon Beta-1a for multiple sclerosis: safety, pharmacology, and biology J Clin Pharmacol 52 798-808

[9] Hartung H-P(2016)COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects Br J Clin Pharmacol 82 380-388

[10] Baker DP(2015)Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE Mult Scler 21 1025-1035